Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to Arch Biopartners. In this capacity, Drs. Smith and Rayner will provide expertise in all aspects of drug development for new drug products emerging from the Arch portfolio, including preclinical planning, clinical trial design, cGMP manufacturing and government relations.
Dr. Smith, the former head of U.S. clinical pharmacology for Roche, has more than 15 years of global drug development experience. He is a Research Professor at SUNY-Buffalo and has more than 80 peer-reviewed publications. Dr. Smith has extensive knowledge in all aspects of drug development, with particular emphasis on innovative translational and quantitative approaches in early phase development to optimize speed and efficient proof of concept delivery.
Dr. Rayner has more than 15 years of drug development experience, working at Roche and CSL-Behring, where he held roles in clinical pharmacology and early development, clinical development, and business development. He has extensive regulatory interaction experience with major health authorities.
Drs. Smith and Rayner are currently directors of d3 Medicine, a global drug development firm they co-founded in 2012.